BACKGROUND: Prostate cancer is the most common malignant tumor among adult men worldwide andthe second most common cause of cancer death. Gleason grading system is a powerful predictor in theprognosis and treatment outcome of prostate carcinoma. OBJECTIVE: This retrospective study aims to evaluate the accuracy of transrectal ultrasound (TRUS)-guided biopsy of the prostate compared to radical prostatectomy specimen in predicting thepathological grading of prostate adenocarcinoma using the Gleason scores between specimens. METHODS: This is a review of 69 patients who underwent radical prostatectomy due to prostate cancerin 2010-2015. The Gleason scores of the transrectal ultrasound biopsies were compared with thesurgical specimen. RESULTS: The biopsy Gleason scores obtained from the TRUS biopsy and the radical prostatectomyspecimens were similar in 79.7% of the cases. In patients with moderately differentiated tumors onbiopsy (Gleason score of 5 to 7), the concordance rate was 83% with upgrading after surgery in 16%of the cases. In poorly-differentiated tumors on biopsy (Gleason score of 8 to 10), 74% revealed thesame score on histopathological examination after radical prostatectomy, while 25% of the caseswere given lower Gleason scores after operation. Overall, 20.3% cases were discrepant by 1 or moreGleason scores after radical prostatectomy. There was a good histopathological correlation betweenTRUS biopsy and prostatectomy specimen {AUC =0.787(p=0.001)}. CONCLUSION The overall accuracy of Gleason score on transrectal ultrasound-guided biopsies inpredicting prostatectomy specimen grade is favorable. It plays a significant role in clinical decisionmaking of patients with prostate carcinoma.

OBJECTIVE: This study aimed to evaluate the clinical utility of power Doppler ultrasonography (PDUS) in the detection of prostate cancer and determine its predictive ability compared to digital rectal examination, serum PSA levels and gray-scale transrectal ultrasonography, using biopsy as the reference standard.

MATERIALS AND METHODS: This is a prospective cross-sectional study of 100 consecutive patients, who underwent prostate needle biopsies at the National Kidney and Transplant Institute. All patients were seen at the Out-patient Department, suspected of having prostate cancer because of abnormally high serum PSA levels (>4 ng/ml) and/or abnormal digital rectal examination. Patients previously diagnosed with prostate cancer were excluded in the study. All patients underwent gry-scale TRUS before power Doppler imaging of the prostate using the Siemens Sonoline Elegra high resolution digital ultrasound with a 6.5 MHz endocavitary probe. After power Doppler imaging, a systematic 12-core and lesion-directed TRUS-guided biopsy of the prostate was performed.

RESULTS: A total of 100 patients (mean age 65, SD 7, range 41-83) were included in this study. Prostate needle biopsy confirmed 37 prostate cancer cases. Of the 37 patients diagnosed with prostate cancer, 18 had an abnormal DRE, 26 had abnormal TRUS findings, and 14 had positive power Doppler flow. PDUS has a positive predictive value of 66.7% and a specificity of 88.9%. Logistic regression analysis with the odds ratio computed at 95% C.I. showed that the probability of having prostate cancer when DRE is positive, PSA is elevated, hypoechoic lesion is present on Gray-scale TRUS and hypervascularity of the peripheral zone is present on PDUS are significantly higher than if all of these tests were negative with PDUS in combination with DRE showing the highest predictive ability for prostate cancer.

CONCLUSION: Power Doppler imaging increases the specificity and positive predictive value of Gray-scale transrectal ultrasound in prostate cancer detection. The addition of PDUS to the screening tool of digital rectal exam increases the probability of the patient having cancer when both tests are positive, thus increasing its predictive power.

Prostate Cancer ; Power Doppler Ultrasonography ; Gray-scale Ultrasonography

AIM

This study aims to evaluate the clinical utility of Power Doppler Ultrasonography (PDUS) in the detection of prostate cancer and determine its predictive ability compared to digital rectal examination, serum PSA levels and gray-scale transrectal ultrasonography, using biopsy as the reference standard.

MATERIALS AND METHODS

This is a prospective cross-sectional study of 49 consecutive patients, who underwent prostate needle biopsies at the National Kidney and Transplant Institute. All patients were seen at the out-patient department and suspected of having prostate cancer because of abnormally high serum PSA levels (>4 ng/ml) and/or abnormal digital rectal examination. Patients previously diagnosed with prostate cancer were excluded in the study. All patients underwent gray-scale TRUS before power Doppler imaging of the prostate using the Siemens Sonoline Elegra high resolution digital ultrasound with a 6.5 MHz endocavitary probe. After power Doppler imaging, a systematic 1 2-core and lesion-directed TRUS-guided biopsy of the prostate was performed.

RESULTS

A total of 49 patients (mean age 64.45, SD 7.53, range 41-79) were included in this study. Prostate needle biopsy confirmed 15 (30.6%) to have prostate cancer. Of the 15 patients diagnosed with prostate cancer, 5 (33.3%) had an abnormal DRE, 10 (66.7%) had abnormal TRUS findings, 3 (20%) had positive power Doppler flow. PDU had a positive predictive value of 60% and a specificity of 94.1 %. Multivariate logistic regression analysis with the odds ratio computed at 95% C.l. showed that the addition of PDUS to the standard procedure for prostate cancer detection using DRE, serum PSA, and TRUS resulted in a higher sensitivity and better overall predictive performance.

CONCLUSION

The overall prostate cancer detection rate was 30.6% with a sensitivity of 66.7% for gray-scale TRUS and 20% for power Doppler ultrasonography. PDUS increased the predictive value and specificity of Gray-scale TRUS. The addition of PDUS to the standard procedure for prostate cancer detection using DRE, serum PSA, and TRUS resulted in a higher sensitivity and better overall predictive performance.

Human ; Prostatic Neoplasms